240 related articles for article (PubMed ID: 21697654)
1. Development of an Fn14 agonistic antibody as an anti-tumor agent.
Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB
MAbs; 2011; 3(4):362-75. PubMed ID: 21697654
[TBL] [Abstract][Full Text] [Related]
2. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB
Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.
Salzmann S; Seher A; Trebing J; Weisenberger D; Rosenthal A; Siegmund D; Wajant H
J Biol Chem; 2013 May; 288(19):13455-66. PubMed ID: 23532848
[TBL] [Abstract][Full Text] [Related]
4. TWEAK signals through JAK-STAT to induce tumor cell apoptosis.
Chapman MS; Wu L; Amatucci A; Ho SN; Michaelson JS
Cytokine; 2013 Jan; 61(1):210-7. PubMed ID: 23107828
[TBL] [Abstract][Full Text] [Related]
5. Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.
Chopra M; Brandl A; Siegmund D; Mottok A; Schäfer V; Biehl M; Kraus S; Bäuerlein CA; Ritz M; Mattenheimer K; Schwinn S; Seher A; Grabinger T; Einsele H; Rosenwald A; Brunner T; Beilhack A; Wajant H
Blood; 2015 Jul; 126(4):437-44. PubMed ID: 26012567
[TBL] [Abstract][Full Text] [Related]
6. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.
Aronin A; Amsili S; Prigozhina TB; Tzdaka K; Rachmilewitz J; Shani N; Tykocinski ML; Dranitzki Elhalel M
PLoS One; 2013; 8(10):e77050. PubMed ID: 24130833
[TBL] [Abstract][Full Text] [Related]
7. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.
Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG
Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934
[TBL] [Abstract][Full Text] [Related]
8. Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.
Prigozhina TB; Szafer F; Aronin A; Tzdaka K; Amsili S; Makdasi E; Shani N; Dranitzki Elhalel M
Cancer Lett; 2017 Aug; 400():99-109. PubMed ID: 28455246
[TBL] [Abstract][Full Text] [Related]
9. Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.
Zaitseva O; Hoffmann A; Löst M; Anany MA; Zhang T; Kucka K; Wiegering A; Otto C; Wajant H
Front Immunol; 2023; 14():1194610. PubMed ID: 37545514
[TBL] [Abstract][Full Text] [Related]
10. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL
Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA
Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630
[TBL] [Abstract][Full Text] [Related]
12. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).
Fick A; Lang I; Schäfer V; Seher A; Trebing J; Weisenberger D; Wajant H
J Biol Chem; 2012 Jan; 287(1):484-495. PubMed ID: 22081603
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.
Nakayama M; Ishidoh K; Kojima Y; Harada N; Kominami E; Okumura K; Yagita H
J Immunol; 2003 Jan; 170(1):341-8. PubMed ID: 12496418
[TBL] [Abstract][Full Text] [Related]
14. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.
Dhruv H; Loftus JC; Narang P; Petit JL; Fameree M; Burton J; Tchegho G; Chow D; Yin H; Al-Abed Y; Berens ME; Tran NL; Meurice N
J Biol Chem; 2013 Nov; 288(45):32261-32276. PubMed ID: 24056367
[TBL] [Abstract][Full Text] [Related]
15. The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system.
Echeverry R; Wu F; Haile WB; Wu J; Yepes M
J Neuroinflammation; 2012 Mar; 9():45. PubMed ID: 22394384
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.
Sanz AB; Sanchez-Niño MD; Carrasco S; Manzarbeitia F; Ruiz-Andres O; Selgas R; Ruiz-Ortega M; Gonzalez-Enguita C; Egido J; Ortiz A
PLoS One; 2012; 7(10):e47440. PubMed ID: 23077618
[TBL] [Abstract][Full Text] [Related]
18. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules.
Brown SA; Hanscom HN; Vu H; Brew SA; Winkles JA
Biochem J; 2006 Jul; 397(2):297-304. PubMed ID: 16526941
[TBL] [Abstract][Full Text] [Related]
19. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG
J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.
Xia Y; Campbell SR; Broder A; Herlitz L; Abadi M; Wu P; Michaelson JS; Burkly LC; Putterman C
Clin Immunol; 2012 Nov; 145(2):108-21. PubMed ID: 22982296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
